{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:50:23Z","timestamp":1790812223309,"version":"4.1.0"},"reference-count":46,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,1,28]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dysregulated expression of BCL-2 family proteins allows cancer cells to escape apoptosis. To counter this, BH3-mimetic drugs that target and inhibit select BCL-2 prosurvival proteins to induce apoptosis have been developed for cancer therapy. Venetoclax, which targets BCL-2, has been effective as therapy for patients with chronic lymphocytic leukemia, and MCL-1\u2013targeting BH3-mimetic drugs have been extensively evaluated in preclinical studies for a range of blood cancers. Recently, BCL-W, a relatively understudied prosurvival member of the BCL-2 protein family, has been reported to be abnormally upregulated in Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), and Hodgkin lymphoma patient samples. Therefore, to determine if BCL-W would be a promising therapeutic target for B-cell lymphomas, we have examined the role of BCL-W in the sustained growth of human BL- and DLBCL-derived cell lines. We found that CRISPR\/CAS9-mediated loss or short hairpin RNA-mediated knockdown of BCL-W expression in selected BL and DLBCL cell lines did not lead to spontaneous apoptosis and had no effect on their sensitivity to a range of BH3-mimetic drugs targeting other BCL-2 prosurvival proteins. Our results suggest that BCL-W is not universally required for the sustained growth and survival of human BL and DLBCL cell lines. Thus, targeting BCL-W in this subset of B-cell lymphomas may not be of broad therapeutic benefit.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000541","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T16:39:47Z","timestamp":1580143187000},"page":"356-366","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["BCL-W is dispensable for the sustained survival of select Burkitt lymphoma and diffuse large B-cell lymphoma cell lines"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1946-5161","authenticated-orcid":false,"given":"Sarah T.","family":"Diepstraten","sequence":"first","affiliation":[{"name":"The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia;"},{"name":"Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Chang","sequence":"additional","affiliation":[{"name":"The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Tai","sequence":"additional","affiliation":[{"name":"The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-nan","family":"Gong","sequence":"additional","affiliation":[{"name":"The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia;"},{"name":"Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9285-3259","authenticated-orcid":false,"given":"Ping","family":"Lan","sequence":"additional","affiliation":[{"name":"Institute for Advanced and Applied Chemical Synthesis, Jinan University, Guangzhou, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1909-7047","authenticated-orcid":false,"given":"Alexander C.","family":"Dowell","sequence":"additional","affiliation":[{"name":"Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham S.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Strasser","sequence":"additional","affiliation":[{"name":"The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia;"},{"name":"Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma L.","family":"Kelly","sequence":"additional","affiliation":[{"name":"The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia;"},{"name":"Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,1,27]]},"reference":[{"issue":"4","key":"2020012711394429500_B1","first-page":"665","article-title":"bcl-w, a novel member of the bcl-2 family, promotes cell survival","volume":"13","author":"Gibson","year":"1996","journal-title":"Oncogene"},{"issue":"21","key":"2020012711394429500_B2","doi-asserted-by":"crossref","first-page":"12424","DOI":"10.1073\/pnas.95.21.12424","article-title":"Apoptosis regulator bcl-w is essential for spermatogenesis but appears otherwise redundant","volume":"95","author":"Print","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2020012711394429500_B3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/ng0398-251","article-title":"Testicular degeneration in Bclw-deficient mice","volume":"18","author":"Ross","year":"1998","journal-title":"Nat Genet"},{"issue":"2","key":"2020012711394429500_B4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrc.2015.17","article-title":"Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies","volume":"16","author":"Delbridge","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2020012711394429500_B5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/cdd.2017.161","article-title":"The BCL-2 arbiters of apoptosis and their growing role as cancer targets","volume":"25","author":"Adams","year":"2018","journal-title":"Cell Death Differ"},{"issue":"4","key":"2020012711394429500_B6","doi-asserted-by":"crossref","first-page":"e1735","DOI":"10.1038\/cddis.2015.105","article-title":"Bid chimeras indicate that most BH3-only proteins can directly activate Bak and Bax, and show no preference for Bak versus Bax","volume":"6","author":"Hockings","year":"2015","journal-title":"Cell Death Dis"},{"issue":"1","key":"2020012711394429500_B7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"issue":"7283","key":"2020012711394429500_B8","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature08822","article-title":"The landscape of somatic copy-number alteration across human cancers","volume":"463","author":"Beroukhim","year":"2010","journal-title":"Nature"},{"issue":"1","key":"2020012711394429500_B9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1182\/blood-2006-06-026500","article-title":"Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas","volume":"109","author":"Mestre-Escorihuela","year":"2007","journal-title":"Blood"},{"issue":"49","key":"2020012711394429500_B10","doi-asserted-by":"crossref","first-page":"7038","DOI":"10.1038\/sj.onc.1210510","article-title":"Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance","volume":"26","author":"Zantl","year":"2007","journal-title":"Oncogene"},{"issue":"1","key":"2020012711394429500_B11","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/blood.V100.1.194","article-title":"Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells","volume":"100","author":"Derenne","year":"2002","journal-title":"Blood"},{"issue":"6","key":"2020012711394429500_B12","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood.V99.6.1885","article-title":"Myeloid cell factor-1 is a critical survival factor for multiple myeloma","volume":"99","author":"Zhang","year":"2002","journal-title":"Blood"},{"issue":"3","key":"2020012711394429500_B13","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov"},{"issue":"1","key":"2020012711394429500_B14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/j.1460-2075.1993.tb05641.x","article-title":"Oct-2 facilitates functional preinitiation complex assembly and is continuously required at the promoter for multiple rounds of transcription","volume":"12","author":"Arnosti","year":"1993","journal-title":"EMBO J"},{"issue":"6","key":"2020012711394429500_B15","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ccell.2018.11.004","article-title":"BH3-mimetic drugs: Blazing the trail for new cancer medicines","volume":"34","author":"Merino","year":"2018","journal-title":"Cancer Cell"},{"issue":"4","key":"2020012711394429500_B16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"2020012711394429500_B17","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"2020012711394429500_B18","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol"},{"key":"2020012711394429500_B19","doi-asserted-by":"crossref","unstructured":"Lin TL , StricklandSA, FiedlerW, et al Phase Ib\/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age \u226565 with acute myelogenous leukemia [abstract]. J Clin Oncol. 2016;34(15_suppl). Abstract 7007.","DOI":"10.1200\/JCO.2016.34.15_suppl.7007"},{"key":"2020012711394429500_B20","doi-asserted-by":"crossref","first-page":"7301","DOI":"10.2147\/OTT.S146228","article-title":"MCL-1 inhibition in cancer treatment","volume":"11","author":"Xiang","year":"2018","journal-title":"OncoTargets Ther"},{"issue":"10","key":"2020012711394429500_B21","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1021\/ml5001867","article-title":"Discovery of a potent and selective BCL-XL inhibitor with in vivo activity","volume":"5","author":"Tao","year":"2014","journal-title":"ACS Med Chem Lett"},{"issue":"9","key":"2020012711394429500_B22","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"issue":"12","key":"2020012711394429500_B23","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol"},{"issue":"5","key":"2020012711394429500_B24","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020012711394429500_B25","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1172\/JCI89486","article-title":"BCL-W has a fundamental role in B cell survival and lymphomagenesis","volume":"127","author":"Adams","year":"2017","journal-title":"J Clin Invest"},{"issue":"22","key":"2020012711394429500_B26","doi-asserted-by":"crossref","first-page":"7119","DOI":"10.1158\/1078-0432.CCR-17-1144","article-title":"Non-Hodgkin and Hodgkin lymphomas select for overexpression of BCLW","volume":"23","author":"Adams","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2020012711394429500_B27","article-title":"Targeting BCL-W and BCL-XL as a therapeutic strategy for Hodgkin lymphoma [published online ahead of print 21 October 2019]","author":"Adams","journal-title":"Leukemia"},{"issue":"1","key":"2020012711394429500_B28","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1038\/s41467-018-05815-z","article-title":"Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity","volume":"9","author":"Soderquist","year":"2018","journal-title":"Nat Commun"},{"issue":"8","key":"2020012711394429500_B29","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.celrep.2015.02.002","article-title":"An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo","volume":"10","author":"Aubrey","year":"2015","journal-title":"Cell Reports"},{"issue":"14","key":"2020012711394429500_B30","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2016-03-704908","article-title":"Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1","volume":"128","author":"Gong","year":"2016","journal-title":"Blood"},{"issue":"40","key":"2020012711394429500_B31","doi-asserted-by":"crossref","first-page":"28824","DOI":"10.1074\/jbc.M113.505370","article-title":"Regulation of mammalian target of rapamycin complex 1 by Bcl-2 and Bcl-XL proteins","volume":"288","author":"Zou","year":"2013","journal-title":"J Biol Chem"},{"issue":"47","key":"2020012711394429500_B32","doi-asserted-by":"crossref","first-page":"18507","DOI":"10.1073\/pnas.0806213105","article-title":"Inducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic rats","volume":"105","author":"Herold","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2020012711394429500_B33","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/humu.20495","article-title":"Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database","volume":"28","author":"Petitjean","year":"2007","journal-title":"Hum Mutat"},{"issue":"5","key":"2020012711394429500_B34","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-15-1191","article-title":"Targeting of BCL2 family proteins with ABT-199 and homoharringtonine reveals BCL2- and MCL1-dependent subgroups of diffuse large B-cell lymphoma","volume":"22","author":"Klanova","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2020012711394429500_B35","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2007-11-124487","article-title":"Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis","volume":"112","author":"Stolz","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2020012711394429500_B36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1101\/gad.232009.113","article-title":"Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53","volume":"28","author":"Kelly","year":"2014","journal-title":"Genes Dev"},{"issue":"9","key":"2020012711394429500_B37","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.1007\/s13277-015-3382-6","article-title":"miR-335 inhibits the proliferation and invasion of clear cell renal cell carcinoma cells through direct suppression of BCL-W","volume":"36","author":"Wang","year":"2015","journal-title":"Tumour Biol"},{"issue":"9","key":"2020012711394429500_B38","first-page":"1863","article-title":"MiRNA-107 enhances chemosensitivity to paclitaxel by targeting antiapoptotic factor Bcl-w in non small cell lung cancer","volume":"7","author":"Lu","year":"2017","journal-title":"Am J Cancer Res"},{"issue":"6","key":"2020012711394429500_B39","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1007\/s13277-015-3075-1","article-title":"MicroRNA-15a induces cell apoptosis and inhibits metastasis by targeting BCL2L2 in non-small cell lung cancer","volume":"36","author":"Yang","year":"2015","journal-title":"Tumour Biol"},{"issue":"1","key":"2020012711394429500_B40","first-page":"250","article-title":"miRNA-195 sensitizes human hepatocellular carcinoma cells to 5-FU by targeting BCL-w","volume":"27","author":"Yang","year":"2012","journal-title":"Oncol Rep"},{"issue":"12","key":"2020012711394429500_B41","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Cancer Discov"},{"issue":"6","key":"2020012711394429500_B42","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","article-title":"Programmed anuclear cell death delimits platelet life span","volume":"128","author":"Mason","year":"2007","journal-title":"Cell"},{"issue":"7626","key":"2020012711394429500_B43","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"issue":"4","key":"2020012711394429500_B44","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41375-018-0261-3","article-title":"Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia","volume":"33","author":"Moujalled","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"2020012711394429500_B45","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41419-019-1568-3","article-title":"BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival","volume":"10","author":"Lee","year":"2019","journal-title":"Cell Death Dis"},{"issue":"5","key":"2020012711394429500_B46","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol Cancer Ther"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/2\/356\/1632656\/advancesadv2019000541.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/2\/356\/1632656\/advancesadv2019000541.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:54:59Z","timestamp":1665622499000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/2\/356\/440609\/BCLW-is-dispensable-for-the-sustained-survival-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,27]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,1,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000541","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,27]]}}}